-
Something wrong with this record ?
The synthesis and influence of the novel bispyridinium compound LB1 on the effectiveness of the standard antidotal treatment of organophosphorus nerve agent intoxicated mice and some structure-activity considerations
J. Kassa, RE. Ambler, LJ. Brown, J. Cummins, AC. Green, CM. Timperley
Language English Country Ireland
Document type Journal Article
- MeSH
- Acetylcholinesterase metabolism MeSH
- Antidotes * chemical synthesis chemistry pharmacology therapeutic use MeSH
- Atropine therapeutic use pharmacology MeSH
- Cholinesterase Inhibitors toxicity MeSH
- Mice MeSH
- Nerve Agents * toxicity MeSH
- Organophosphorus Compounds * toxicity MeSH
- Oximes chemistry MeSH
- Pyridinium Compounds * chemical synthesis chemistry therapeutic use pharmacology MeSH
- Soman toxicity MeSH
- Trimedoxime chemistry chemical synthesis pharmacology therapeutic use MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
The design of MB327, a bispyridinium compound that ameliorates the nicotinic effects of acute organophosphorus nerve agent (NA) intoxication, followed an observation made by the German pharmacologist Klaus Schoene in the 1970s, who noted therapeutic activity in bispyridinium molecules missing the usual oxime group, CHNOH. Some of these compounds protected mice against soman. One structurally related to obidoxime called HY10 had this action. Its oxime moieties were capped by tert-butyl groups: CH=NOtBu. We modified HY10 by changing the bridge between the pyridinium units from a dimethylene ether to a trimethylene group (CH2OCH2 → CH2CH2CH2) and prepared a novel relative of trimedoxime, called LB1, whose synthesis and stereochemistry are described. Unlike obidoxime or trimedoxime, LB1 because of its capped oxime groups, cannot directly reactivate NA inhibited acetylcholinesterase. Its antidotal activity in mice is now reported. The therapeutic efficacy of LB1, atropine alone, atropine with LB1, atropine with an oxime (HI-6, obidoxime or trimedoxime), and atropine with an oxime and LB1, was studied by determining the LD50 values of the NAs soman, sarin, or tabun in mice treated with these compounds or mixtures. LB1 exceeded MB327 in toxicity and its activity was insufficient for a useful addition to the current standard antidotal treatment (protective ratio data are compared to those of MB327). Although this study produced largely negative biological results, the therapeutically beneficial mechanism of the effective bispyridinium non-oxime analogues is unclear, and has been demonstrated only in vivo. The present study points out directions in structural optimisation unlikely to yield the desired therapeutic outcomes and provides a literature review that could promote creative thinking for the design of widely-desirable non-oxime therapeutics for anticholinesterase inhibitors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015665
- 003
- CZ-PrNML
- 005
- 20250731091145.0
- 007
- ta
- 008
- 250708e20250308ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cbi.2025.111470 $2 doi
- 035 __
- $a (PubMed)40058717
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Kassa, Jiri $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
- 245 14
- $a The synthesis and influence of the novel bispyridinium compound LB1 on the effectiveness of the standard antidotal treatment of organophosphorus nerve agent intoxicated mice and some structure-activity considerations / $c J. Kassa, RE. Ambler, LJ. Brown, J. Cummins, AC. Green, CM. Timperley
- 520 9_
- $a The design of MB327, a bispyridinium compound that ameliorates the nicotinic effects of acute organophosphorus nerve agent (NA) intoxication, followed an observation made by the German pharmacologist Klaus Schoene in the 1970s, who noted therapeutic activity in bispyridinium molecules missing the usual oxime group, CHNOH. Some of these compounds protected mice against soman. One structurally related to obidoxime called HY10 had this action. Its oxime moieties were capped by tert-butyl groups: CH=NOtBu. We modified HY10 by changing the bridge between the pyridinium units from a dimethylene ether to a trimethylene group (CH2OCH2 → CH2CH2CH2) and prepared a novel relative of trimedoxime, called LB1, whose synthesis and stereochemistry are described. Unlike obidoxime or trimedoxime, LB1 because of its capped oxime groups, cannot directly reactivate NA inhibited acetylcholinesterase. Its antidotal activity in mice is now reported. The therapeutic efficacy of LB1, atropine alone, atropine with LB1, atropine with an oxime (HI-6, obidoxime or trimedoxime), and atropine with an oxime and LB1, was studied by determining the LD50 values of the NAs soman, sarin, or tabun in mice treated with these compounds or mixtures. LB1 exceeded MB327 in toxicity and its activity was insufficient for a useful addition to the current standard antidotal treatment (protective ratio data are compared to those of MB327). Although this study produced largely negative biological results, the therapeutically beneficial mechanism of the effective bispyridinium non-oxime analogues is unclear, and has been demonstrated only in vivo. The present study points out directions in structural optimisation unlikely to yield the desired therapeutic outcomes and provides a literature review that could promote creative thinking for the design of widely-desirable non-oxime therapeutics for anticholinesterase inhibitors.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a pyridinové sloučeniny $x chemická syntéza $x chemie $x terapeutické užití $x farmakologie $7 D011726
- 650 _2
- $a myši $7 D051379
- 650 12
- $a antidota $x chemická syntéza $x chemie $x farmakologie $x terapeutické užití $7 D000931
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 12
- $a nervová bojová látka $x toxicita $7 D000067397
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a soman $x toxicita $7 D012999
- 650 12
- $a organofosforové sloučeniny $x toxicita $7 D009943
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a trimedoxim $x chemie $x chemická syntéza $x farmakologie $x terapeutické užití $7 D014289
- 650 _2
- $a cholinesterasové inhibitory $x toxicita $7 D002800
- 650 _2
- $a oximy $x chemie $7 D010091
- 650 _2
- $a atropin $x terapeutické užití $x farmakologie $7 D001285
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ambler, Rachael E $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
- 700 1_
- $a Brown, Lynda J $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
- 700 1_
- $a Cummins, Jaime $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
- 700 1_
- $a Green, A Christopher $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
- 700 1_
- $a Timperley, Christopher M $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom. Electronic address: cmtimperley@dstl.gov.uk
- 773 0_
- $w MED00002111 $t Chemico-biological interactions $x 1872-7786 $g Roč. 413 (20250308), s. 111470
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40058717 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091140 $b ABA008
- 999 __
- $a ok $b bmc $g 2366490 $s 1252790
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 413 $c - $d 111470 $e 20250308 $i 1872-7786 $m Chemico-biological interactions $n Chem Biol Interact $x MED00002111
- LZP __
- $a Pubmed-20250708